Cargando…

Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection

BACKGROUND: Fatigue is a common symptom of chronic hepatitis C virus (HCV) infection and a frequent side-effect of peginterferon/ribavirin (PR) therapy for HCV. This study evaluated the impact of adding the oral HCV NS3/4A protease inhibitor simeprevir to PR on patient-reported fatigue and health st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scott, Jane, Rosa, Kathleen, Fu, Min, Cerri, Karin, Peeters, Monika, Beumont, Maria, Zeuzem, Stefan, Evon, Donna M, Gilles, Leen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4162924/ https://www.ncbi.nlm.nih.gov/pubmed/25164700 http://dx.doi.org/10.1186/1471-2334-14-465

Ejemplares similares

Simeprevir for the treatment of hepatitis C virus infection
por: Izquierdo, Laure, et al.
Publicado: (2014)

Validation of the Fatigue Severity Scale in chronic hepatitis C
por: Rosa, Kathleen, et al.
Publicado: (2014)

New treatments for genotype 1 chronic hepatitis C – focus on simeprevir
por: Kanda, Tatsuo, et al.
Publicado: (2014)

Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study
por: Gane, Edward J., et al.
Publicado: (2017)

Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus‐infected patients: Long‐term follow‐up results from the open‐label, Phase II IMPACT study
por: Lawitz, Eric, et al.
Publicado: (2020)

Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C
por: Sarkar, Souvik, et al.
Publicado: (2015)

Treatment of Recurrent Hepatitis C Genotype-4 Post-Liver Transplantation with Sofosbuvir plus Simeprevir
por: Ascha, Mustafa, et al.
Publicado: (2015)

Simeprevir with peginterferon/ribavirin for patients with hepatitis C virus genotype 1: high frequency of viral relapse in elderly patients
por: Watanabe, Takao, et al.
Publicado: (2016)

Sofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation
por: Issa, D., et al.
Publicado: (2016)

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)
por: Lawitz, Eric, et al.
Publicado: (2016)

Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results
por: Bichoupan, Kian, et al.
Publicado: (2017)

Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir
por: De Meyer, Sandra, et al.
Publicado: (2014)

Benefit–risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir
por: Gaetano, John N
Publicado: (2014)

Sofosbuvir in combination with ribavirin or simeprevir: real-life study of patients with hepatitis C genotype 4
por: Abdel-Moneim, Adel, et al.
Publicado: (2019)

Pre-existence and Persistence of Resistant Minority Hepatitis C Virus Variants in Genotype 1-Infected Patients Treated With Simeprevir/Peginterferon/Ribavirin
por: Fevery, Bart, et al.
Publicado: (2016)

Hepatitis C Virus Infection Increases Fatigue in Health Care Workers
por: Catania, Vito Emanuele, et al.
Publicado: (2020)

Drug–Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir
por: Ouwerkerk-Mahadevan, Sivi, et al.
Publicado: (2015)

Simeprevir with pegylated interferon alfa 2a plus ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a meta-analysis and historical comparison
por: Andersohn, Frank, et al.
Publicado: (2016)

An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)
por: Asselah, Tarik, et al.
Publicado: (2016)

Impact of Soluble CD26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection
por: Söderholm, Jonas, et al.
Publicado: (2013)

Real-World Effectiveness of Simeprevir-containing Regimens Among Patients With Chronic Hepatitis C Virus: The SONET Study
por: Alam, Imtiaz, et al.
Publicado: (2016)

Evaluation of the Pharmacokinetics and Renal Excretion of Simeprevir in Subjects with Renal Impairment
por: Ouwerkerk-Mahadevan, Sivi, et al.
Publicado: (2015)

Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study
por: Kwo, Paul, et al.
Publicado: (2016)

Successful treatment of hepatitis C genotype 4 using sofosbuvir, daclatasvir, simeprevir and ribavirin in Egyptian patients with direct-acting antiviral agent treatment failure
por: Mohamed, Hala, et al.
Publicado: (2022)

JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study
por: Takehara, Tetsuo, et al.
Publicado: (2020)

Sofosbuvir and Simeprevir Therapy for Recurrent Hepatitis C Infection After Liver Transplantation
por: Khemichian, Saro, et al.
Publicado: (2015)

Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study
por: Hayashi, Norio, et al.
Publicado: (2013)

Treatment of hepatitis C virus genotype 4 in the DAA era
por: Di Biagio, Antonio, et al.
Publicado: (2018)

A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection
por: Zoulim, Fabien, et al.
Publicado: (2018)

Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study
por: Gaeta, Giovanni Battista, et al.
Publicado: (2018)

Photo-induced drug eruption in a patient on combination simeprevir/sofosbuvir for hepatitis C
por: Eyre, Zachary W., et al.
Publicado: (2016)

The efficacy of integrated hepatitis C virus treatment in relieving fatigue in people who inject drugs: a randomized controlled trial
por: Vold, Jørn Henrik, et al.
Publicado: (2023)

Sustained Virological Response after 8-Week Treatment of Simeprevir with Peginterferon α-2a plus Ribavirin in a Japanese Female with Hepatitis C Virus Genotype 1b and IL28B Minor Genotype
por: Kanda, Tatsuo, et al.
Publicado: (2015)

Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus
por: Tamai, Hideyuki, et al.
Publicado: (2017)

Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C
por: Yamagiwa, Satoshi, et al.
Publicado: (2017)

Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes
por: Chaturvedi, Nimisha, et al.
Publicado: (2019)

Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection
por: Weiler, Nina, et al.
Publicado: (2016)

Risk factors for hepatitis C virus infection among Koreans according to the hepatitis C virus genotype.
por: Kim, Young Sik, et al.
Publicado: (2002)

Distribution of Hepatitis C Virus Genotypes Among Patients With Hepatitis C Virus Infection in Hormozgan, Iran
por: Mousavi, Seyedeh Farzaneh, et al.
Publicado: (2013)

Distribution of Hepatitis C Virus Genotypes in Bahrain
por: Janahi, Essam M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_a07tu4gscur2bgoqn491b8turg